Evidence-based insights into peptide protocols, safety research, and optimization strategies. Built on clinical rigor, powered by community knowledge.
Get weekly insights on peptide protocols, safety updates, and optimization strategies delivered to your inbox.
No spam. Unsubscribe anytime. Clinical rigor, always.
Deep dives into peptide science — evidence-graded, honestly reported
We tested every peptide tracker app in 2026. Here's what we found, including where our competitors beat us.
The peptide tracker market went from empty to 15+ apps in 12 months. We tested them all and scored them on what matters: safety features, PK modelling, multi-compound support, and price. Pinned is ours. We're transparent about that.
Comprehensive outcome research with safety data and practical protocol references
Detailed compound profiles with mechanisms, safety data, and dosing protocols
Evidence-based supplement stacks designed to support your peptide protocols
Evidence-graded testosterone profiles by ester and formulation, with safety data and peptide alternatives
35+
Articles
18
Categories
RFK said peptides are back. The FDA hasn't published the rule change yet. Here's what's actually happening.
The FDA's 2026 peptide reclassification is a regulatory process, not a completed rule change. Seven compounds face PCAC review in July 2026, legal access requires a prescription, and the grey market remains unchanged until the FDA publishes.
HPTA recovery after testosterone therapy takes far longer than forums claim. Established PCT has limits, and peptides offer a mechanistically compelling but clinically unproven layer on top.
Exogenous testosterone suppresses the hypothalamic-pituitary-testicular axis at every level. Recovery is measured in months to years, not weeks. This article maps the clinical timeline, examines where Kisspeptin-10, triptorelin, and GH secretagogues fit, and is honest about what the evidence does and does not support.
The same TRT protocol becomes a fundamentally different risk proposition at 30 than at 50. Here's where the calculus shifts, and where peptides start winning specific trades.
After 35, cardiovascular remodeling accelerates, prostate risk compounds, and HPTA recovery narrows. This article maps the age-stratified risk data for TRT and identifies where GH secretagogues, the Wolverine Stack, and Sermorelin offer lower-cost alternatives for specific outcomes.
You're spending $200–500/month on biological software and tracking it in a Notes app. The compounds aren't the problem. The total absence of protocol discipline is.
Peptide access exploded in 2026. Protocol discipline didn't follow. Most users are dosing from Reddit consensus, ignoring half-lives, missing timing windows, and running zero safety baselines. This article maps the specific failure modes, the insulin trap, the NO floor, the receptor ceiling, the sedentary trap, and what precision tracking actually looks like by comparison.
Two sister peptides from the same Cold War lab, one calms the emotional floor, the other raises the cognitive ceiling. The mechanistic case for stacking them is architecturally compelling. The clinical evidence for the combination doesn't exist yet.
Selank and Semax are sister heptapeptides engineered with the same glyproline stability tail but from opposite parent molecules, tuftsin (immune) and ACTH (stress). They converge on BDNF through completely different upstream pathways, covering complementary neurochemical territory. This article examines the mechanistic case for combining them, the cofactors that determine whether either signal lands, and where the evidence stops short.
Tirzepatide's insulin-sensitivity effect comes mostly from direct metabolic reprogramming, not weight loss. MOTS-c bypasses the insulin receptor entirely. The Khavinson bioregulators target β-cell regeneration via epigenetics. The three stories land at very different evidence grades — and the highest-impact decision in the whole class is sourcing.
Peptide therapy for insulin sensitivity now spans three distinct mechanistic classes: incretin agonists (GLP-1, tirzepatide, retatrutide) acting at the hormonal layer, mitochondrial-derived peptides (MOTS-c) acting at the cellular-energy layer via AMPK, and epigenetic bioregulators (Khavinson peptides, Pancragen) attempting to restore gene expression in β-cells. Weight loss explains only 13–21% of tirzepatide's HOMA-IR improvement — the rest is direct metabolic reprogramming. MOTS-c is an exercise mimetic in early trials. Bioregulators are a Russian-literature frontier awaiting Western replication. Sourcing is the biggest preventable harm in the whole class.
A D-retro-inverso peptide that selectively kills senescent cells by disrupting the FOXO4-p53 survival interaction, triggering mitochondrial apoptosis in aged 'zombie' cells while sparing healthy tissue.
FOXO4-DRI breaks the molecular shield that keeps senescent cells alive. By freeing p53 from FOXO4 sequestration, it triggers selective apoptosis in aged cells, restoring kidney function, testosterone levels, and tissue vitality in preclinical models.
A selective ghrelin mimetic that triggers your pituitary to release growth hormone without touching cortisol, prolactin, or appetite.
Ipamorelin is a synthetic pentapeptide and the first truly selective growth hormone secretagogue. It binds the GHS-R1a receptor to trigger pulsatile GH release without the hormonal side-channel activation that defined earlier peptides like GHRP-6.
A synthetic GHRH analog that tells your pituitary to release its own growth hormone, not inject someone else's.
CJC-1295 is a 29-amino acid GHRH analog engineered to resist enzymatic breakdown. It stimulates endogenous GH pulses rather than flooding the system with synthetic hormone, offering a fundamentally different risk-benefit profile to direct HGH therapy.
A naturally occurring tripeptide locked inside your collagen that modulates 4,192 human genes, acts as a safe copper chaperone, and signals systemic repair, with plasma levels dropping 60% between ages 20 and 60.
GHK-Cu (Glycyl-L-Histidyl-L-Lysine) is a naturally occurring tripeptide embedded in Type I collagen. Liberated during tissue injury, it acts as a master repair signal modulating 4,192 human genes (roughly one-third of the genome). It drives collagen synthesis, delivers copper safely to enzymes like Superoxide Dismutase via a unique square-planar pyramid configuration, and shows emerging potential in gut barrier repair (SIRT1/STAT3) and COPD reversal (127-gene signature). Plasma levels decline 60% by age 60. Clinical protocols use a biphasic 30-day cycle (1mg escalating to 2mg) with a mandatory 30-day rest. FDA Category 2 restricts legal compounding for systemic use. Contraindicated in active malignancies and Wilson's Disease.
A four-amino-acid peptide that activates telomerase, remodels chromatin, and restores melatonin synthesis from the pineal gland — addressing five hallmarks of aging simultaneously. The Russian clinical data spans 12–15 years. Independent Western replication barely exists.
Epitalon (AEDG) is a synthetic tetrapeptide modeled after the bovine pineal extract Epithalamin. It upregulates hTERT to activate telomerase, remodels heterochromatin to re-access silenced genes, restores endogenous melatonin production (160% increase in clinical trials), and demonstrated a 28% decrease in overall mortality over a 12-year human follow-up. A 2025 study revealed selective ALT pathway activation in cancer cells. The compound remains investigational — nearly all positive data originates from a single institutional network in St. Petersburg, and independent Western replication is virtually absent.
A 16-amino-acid mitochondrial messenger that mimics exercise at the cellular level — activating AMPK, reprogramming metabolism, and writing survival instructions directly into the nucleus. The science is striking. The stability problem is brutal.
MOTS-c is a mitochondrial-derived peptide (mitokine) that acts as an exercise mimetic through the Folate-AICAR-AMPK axis. It translocates to the nucleus under metabolic stress, enhances glucose uptake via GLUT4, promotes white-to-brown fat conversion, and reprograms immune cells toward anti-inflammatory phenotypes. A natural longevity variant (K14Q) exists in East Asian populations. Clinical translation is hampered by extreme instability (85–90% activity loss in 2–3 hours at room temperature) and a circulating half-life of only 1–2 hours.
The biochemical cofactors your body needs to support CJC-1295 therapy.
Evidence-based supplement companion for CJC-1295 , a synthetic GHRH analog that tells your pituitary to release its own growth hormone, not inject someone else's.
The first synthetic testosterone ester (1936), with a 2-4.5 day half-life that demands daily or EOD dosing. What the clinical data says about the fertility paradox, rapid washout safety, microdosing, and why this 'relic' is the precision tool of modern endocrinology.
Evidence-graded profile of testosterone propionate: the fastest-acting injectable ester, its fertility paradox from murine data, the washout safety net for women and diagnostics, PIP solutions through microdosing, circadian alignment, age-stratified risk, and peptide alternatives.